ATR Inhibition Induces CDK1–SPOP Signaling and Enhances Anti–PD-L1 Cytotoxicity in Prostate CancerZhe Tang, Timothy C. Thompson, Patrick G. Pilié et al.|Clinical Cancer Research|2021Cited by 145
PARP and CDK4/6 Inhibitor Combination Therapy Induces Apoptosis and Suppresses Neuroendocrine Differentiation in Prostate CancerCheng Wu, Timothy C. Thompson, Shan Peng et al.|Molecular Cancer Therapeutics|2021Cited by 58
SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth SuppressionChuandong Geng, Timothy C. Thompson, Man-Chao Zhang et al.|Clinical Cancer Research|2023Cited by 24
Combined in vitro and in silico analyses of <scp>FGFR1</scp> variants: genotype‐phenotype study in idiopathic hypogonadotropic hypogonadismDaoqi Wang, Jihong Liu, Yonghua Niu et al.|Clinical Genetics|2020Cited by 9
An isolated hypogonadotropic hypogonadism male with a novel de novo <i>FGFR1</i> mutation fathered a normal son evidenced by prenatal genetic diagnosisHao Xu, Jihong Liu, Zongzhe Li et al.|Andrologia|2020Cited by 1